Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial by Shitara, Kohei, MD, Doi, Toshihiko, MD, Dvorkin, Mikhail, MD, Mansoor, Wasat, MD, Arkenau, Hendrik-Tobias, MD, Prokharau, Aliaksandr, Prof, Alsina, Maria, MD, Ghidini, Michele, MD, Faustino, Catia, MD, Gorbunova, Vera, MD, Zhavrid, Edvard, Prof, Nishikawa, Kazuhiro, MD, Hosokawa, Ayumu, MD, Yalçın, Şuayib, Prof, Fujitani, Kazumasa, MD, Beretta, Giordano D, MD, Cutsem, Eric Van, Prof, Winkler, Robert E, MD, Makris, Lukas, PhD, Ilson, David H, MD, Tabernero, Josep, MD

Get full text

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, place... by Fuchs, Charles S, MD, Shitara, Kohei, MD, Di Bartolomeo, Maria, MD, Lonardi, Sara, MD, Al-Batran, Salah-Eddin, Prof, Van Cutsem, Eric, Prof, Ilson, David H, MD, Alsina, Maria, MD, Chau, Ian, MD, Lacy, Jill, Prof, Ducreux, Michel, Prof, Mendez, Guillermo Ariel, MD, Alavez, Alejandro Molina, MD, Takahari, Daisuke, MD, Mansoor, Wasat, MD, Enzinger, Peter C, MD, Gorbounova, Vera, MD, Wainberg, Zev A, MD, Hegewisch-Becker, Susanna, Prof, Ferry, David, MD, Lin, Ji, PhD, Carlesi, Roberto, MD, Das, Mayukh, MD, Shah, Manish A, MD

Get full text

Chemotherapeutic Options for Gastroesophageal Junction Tumors by Ku, Geoffrey Y., MD, Ilson, David H., MD, PhD

Get full text

Targeted Agents and Esophageal Cancer—The Next Step? by Aklilu, Mebea, MD, Ilson, David H., MD

Get full text

Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer by Hawkes, Eliza, MD, Chau, Ian, MD, Ilson, David H., MD, Cunningham, David, MD, FRCP

Get full text

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial by Janjigian, Yelena Y, MD, Maron, Steven B, MD, Chatila, Walid K, MS, Millang, Brittanie, MPH, Chavan, Shweta S, PhD, Alterman, Carly, BA, Chou, Joanne F, MPH, Segal, Michal F, RN, Simmons, Marc Z, MD, Momtaz, Parisa, MD, Shcherba, Marina, MD, Ku, Geoffrey Y, MD, Zervoudakis, Alice, MD, Won, Elizabeth S, MD, Kelsen, David P, Prof, Ilson, David H, Prof, Nagy, Rebecca J, MS, Lanman, Richard B, MD, Ptashkin, Ryan N, MS, Donoghue, Mark T A, PhD, Capanu, Marinela, PhD, Taylor, Barry S, PhD, Solit, David B, Prof, Schultz, Nikolaus, PhD, Hechtman, Jaclyn F, MD

Get full text

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial by Safran, Howard P, Prof, Winter, Kathryn, MS, Ilson, David H, Prof, Wigle, Dennis, Prof, DiPetrillo, Thomas, MD, Haddock, Michael G, Prof, Hong, Theodore S, Prof, Leichman, Lawrence P, Prof, Rajdev, Lakshmi, MD, Resnick, Murray, Prof, Kachnic, Lisa A, Prof, Seaward, Samantha, MD, Mamon, Harvey, MD, Diaz Pardo, Dayssy Alexandra, MD, Anderson, Carryn M, MD, Shen, Xinglei, MD, Sharma, Anand K, Prof, Katz, Alan W, MD, Salo, Jonathan, MD, Leonard, Kara L, MD, Moughan, Jennifer, MS, Crane, Christopher H, MD

Get full text

First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 tria... by Cytryn, Samuel L, MD, Moy, Ryan H, MD, Cowzer, Darren, MBBCh, Shah, Ronak H, MS, Chou, Joanne F, MPH, Joshi, Smita S, MD, Ku, Geoffrey Y, MD, Maron, Steven B, MD, Desai, Avni, MD, Yang, Jessica, MD, Sugarman, Ryan, MD, Rao, Devika, MD, Goldberg, Zoe, MD, Charalambous, Carmelina, MPhil, Lapshina, Maria, BE, Antoine, Ariel, BS, Socolow, Fiona, BA, Trivedi, Nikhil, BS, Capanu, Marinela, PhD, Gerdes, Hans, Prof, Schattner, Mark A, Prof, Simmons, Marc, MD, Lacouture, Mario E, MD, Paroder, Viktoriya, MD, Tang, Laura H, Prof, Shia, Jinru, Prof, Ilson, David H, Prof, Solit, David B, Prof, Berger, Michael F, PhD, Janjigian, Yelena Y, MD

Get full text